ArticleWorld journal of clinical cases2022
Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review.
Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Gallbladder neuroendocrine neoplasms: a review.Abdominal radiology (New York) · 2026Review
- Two cases of large cell neuroendocrine carcinoma of the gallbladder: case reports and systemic literature review.Frontiers in medicine · 2026Article
- Clinicopathological characteristics and treatment outcomes of biliary neuroendocrine carcinoma: a single-center case series and literature review.Frontiers in oncology · 2026Article
- Demographic and temporal variations in gallbladder adenocarcinoma and neuroendocrine carcinoma: insights from a retrospective analysis of the national cancer database.Cancer causes & control : CCC · 2025Article
- Clinicopathologic and molecular characteristics of neuroendocrine carcinomas of the gallbladder.Histology and histopathology · 2025Article
- Endoscopic Ultrasound-Guided Diagnosis of Gallbladder Mixed Neuroendocrine Non-Neuroendocrine Tumor With an Anomalous Pancreaticobiliary Junction.ACG case reports journal · 2024Article
- Does the size of the neuroendocrine-carcinoma component determine the prognosis of gallbladder cancer?Frontiers in endocrinology · 2024Article
- Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas.Frontiers in endocrinology · 2024Article
- Effects of cytoreductive surgery combined with hyperthermic perfusion chemotherapy on prognosis of patients with advanced gallbladder cancer.World journal of gastrointestinal surgery · 2023Article
- Comparison of the clinical features and long-term prognosis of gallbladder neuroendocrine carcinoma versus gallbladder adenocarcinoma: A propensity score-matched analysis.Biomolecules & biomedicine · 2023Article
- Long-Term Complete Response of Unresectable Small-Cell Neuroendocrine Carcinoma of the Gallbladder following Chemotherapy and Radiotherapy: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder neuroendocrine carcinoma (GB-NEC) has a low incidence rate; therefore, its clinical characteristics, diagnosis, treatment and prognosis are not well explored.
aimTo review recent research and analyze corresponding data in the Surveillance Epidemiology and End Results (SEER) database.
methodsData of GB-NEC (
resultsThe GB-NEC incidence rate was 1.6% (of all gallbladder carcinomas), male to female ratio was 1:2 and the median survival time was 7 mo. The 1-, 2-, 3- and 5-year overall survival (OS) was 36.6%, 17.8%, 13.2% and 7.3% respectively. Serum chromogranin A levels may be a specific tumor marker for the diagnosis of GB-NEC. Elevated carcinoembryonic antigen, carbohydrate antigen (CA)-19-9 and CA-125 levels were associated with poor prognosis. Age [hazard ratio (HR) = 1.027, 95% confidence interval (CI): 1.006-1.047,
conclusionThe clinical manifestations and prognosis of GB-NEC are similar to GB-ADC, but the treatment is completely different. Early diagnosis and treatment are the top priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.